Radiopharmaceutical specialist Aktis seeks an IPO [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Aktis Oncology has become the first biotechnology company to file for an initial public offering in several weeks, outlining on Friday a stock issuance to help advance a pipeline of radiopharmaceuticals for cancer. Aktis specializes in what it calls “miniprotein radioconjugates,” which it believes to be capable of accessing tumor targets that are “outside the scope” of current radiopharmaceutical technologies, according to the company's IPO prospectus. Its first prospect is currently in early-stage testing and aimed at a protein called Nectin-4 that's expressed by bladder cancers as well as other solid tumors. Aktis has a partnership in place with Eli Lilly and has received investments from multiple large pharmaceutical companies , among them Merck & Co., Novartis and Bristol Myers Squibb. It raised about $346 million in private financing before submitting its IPO paperwork. 2025 has largely been a year to forget for biotech IPOs. Already in the throes of a prolonged slowdown
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- “Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer [Yahoo! Finance]Yahoo! Finance
- SCHD vs. VYM: A Higher Yield Or High Total Return Potential [Yahoo! Finance]Yahoo! Finance
- SCHD Offers a Higher Yield While FDVV Grows Faster [Yahoo! Finance]Yahoo! Finance
- The Best Dividend ETF to Buy: SCHD Pays a High Yield While VIG Focuses on Dividend Growth [Yahoo! Finance]Yahoo! Finance
- Dividend ETF Matchup: SCHD Offers Higher Yield While VIG Leads in Growth [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 12/4/25 - Form 8-K
- 12/3/25 - Form 424B5
- 12/2/25 - Form FWP
- MRK's page on the SEC website